Matsubara, N., Mukai, H., Hosono, A., Onomura, M., Sasaki, M., Yajima, Y., . . . Zurth, C. (2017). Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol.
Citação norma ChicagoMatsubara, Nobuaki, et al. "Erratum To: Phase 1 Study of Darolutamide (ODM-201), a New-generation Androgen Receptor Antagonist, in Japanese Patients With Metastatic Castration-resistant Prostate Cancer." Cancer Chemother Pharmacol 2017.
ציטוט MLAMatsubara, Nobuaki, et al. "Erratum To: Phase 1 Study of Darolutamide (ODM-201), a New-generation Androgen Receptor Antagonist, in Japanese Patients With Metastatic Castration-resistant Prostate Cancer." Cancer Chemother Pharmacol 2017.